Recursion Pharmaceuticals, a biotech start-up in Salt Lake City today announced the formation of its Business Advisory Panel. The first appointment to the Advisory Panel is H. Perry Fell, MBA, Ph.D. Perry is a distinguished scientist and leader who most prominently co-founded Seattle Genetics (NASDAQ: SGEN) and served as its CEO from start-up through IPO.
Dr. Dean Y. Li, CSO of Recursion and the Vice-Dean of Research at the University of Utah Health Sciences Center adds: “We are so pleased to have Perry Join us. Perry’s experience at Bristol-Myers Squibb, his insight to grab the opportunity to spin out its technology to build Seattle Genetics, and their pioneering efforts to develop drug-antibody conjugates provides us with a role model we hope to learn from and emulate. I am excited not only for what Recursion will do for the rare-disease drug-discovery space, but also what it will mean for Salt Lake City as we seek to grow one of the most innovative pharmaceutical companies in the world right here at the foot of the Wasatch.”
Dr. Fell, along with several others to be announced at a later date, will advise Recursion Pharmaceuticals on a wide range of topics including business strategy and business development.
H. Perry Fell, MBA, Ph.D. – Dr. Perry Fell is an experienced researcher who has had great success as a scientist-founder and scientist-CEO. Perry brings with him vast experience and wisdom in overcoming both scientific and business challenges in the life sciences. He was the Director of Molecular Immunology at Bristol-Myers Squibb Pharmaceutical Research Institute from 1989 to 1997. In 1997, he co-founded Seattle Genetics (NASDAQ: SGEN), and served as the CEO from start-up through IPO. At Seattle Genetics, Dr. Fell and his team pioneered the use of antibody-drug conjugates for the treatment of various cancers. He subsequently served as the Chairman of the Board of Seattle Genetics from 2002-2004. From 2004-2009, Perry was the Chairman, CEO, and President of NanoString Technologies (NASDAQ: NSTG). Perry is currently the Chairman of Prevencio, a company dedicated to bringing new diagnostics to the ER, cardiology clinics, and clinical laboratories.
Recursion Pharmaceuticals is an emerging biotechnology company based in Salt Lake City. Recursion combines experimental biology and bioinformatics with artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, oncology, and diagnostics. Recursion’s ultimate vision is to leverage technology to build a robust and reliable map of human cellular biology, which would enable a radical shift in the pace and scale at which new treatments could benefit patients. Learn more at www.recursionpharma.com, or connect on Twitter, Facebook, and LinkedIn.